On January 9, 2023 LinKinVax, a clinical-stage biotechnology company reported capital funding for a total of €7,3 M from several individual tech executive investors including the co-founder André-Jacques Auberton-Hervé and its newest investor In-Q-Tel, Inc. (IQT), the non-profit strategic investor which delivers cutting-edge and critically needed technology capabilities that contribute to the national security of the United States and its allies (Press release, LinKinVax, JAN 9, 2023, https://ennodc.com/linkinvax-just-completed-a-new-round-of-financing-initiated-in-2022-for-a-total-of-e73-m-supporting-its-next-series-a-round-up-to-e-50-m/ [SID1234648590]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This investment contributes to a first capital funding supporting LinKinVax next series A round up to €50 M. It signals that LinKinVax has huge capabilities to accelerate the clinical development of its innovative protein-based vaccine platform, which can be tuned to address multiple pathogens with adaptability to mutations including viral or bacterial infectious diseases and cancer treatments – HIV, SarsCov2, HPV, papillomavirus-related cancers, chlamydia.
LinKinVax’s innovative technology directly targets dendritic cells ("DC"), which play a crucial role in the immune system, stimulating and regulating immune responses. It is predicated on work by the Vaccine Research Institute/Inserm (VRI) in which Inserm, University of Paris Est Créteil (UPEC), and the Mondor Institute of Biomedical Research (IMRB) participate. Thanks to the potential of its technology platform and the advances in its portfolio (Phase I/IIa on a first indication), LinKinVax aims to make a decisive contribution to the global public health challenges of infectious diseases and cancer.
J.D. Englehart, Director, IQT International Ltd UK:
"We are impressed by LinKinVax’s team and its vision for developing world-class vaccine technology. Their work demonstrates great potential for a robust vaccine portfolio to combat emerging and existing infectious diseases."
André-Jacques Auberton-Hervé, CEO and co-founder of LinKinVax commented:
"We are grateful that our breakthrough vaccine technology, designed to respond to high and growing global need, generated interest from In-Q-Tel. Based on the unprecedented potential of our protein-based vaccine platform, In-Q-Tel is supporting us in our next series A round up to €50 Million, allowing to push ahead the next stages of our ambitious clinical program. Our objective is to provide effective vaccines as rapidly as possible to help address the public health challenges linked to the various pathogens we are targeting."
LinKinVax has already risen to prominence in the French sector, with Bpifrance granting it €31 Million under a Covid-related PIA PSCP program and Government "Plan Relance". This new financing, completed in December 2022, includes a seed funding from private shareholders, beginning of 2022.